Author:
Hu Xi-Chun,Zhang Qingyuan,Wang Leiping,Zhang Jian,Ouyang Quchang,Wang Xiaojia,Li Wei,Xie Weimin,Tong Zhongsheng,Wang Shusen,Xu Faliang,Sun Tao,Liu Wei,Chen Zhendong,Wu Jinsheng,Wang Ying,Wang Haixia,Yan Min,Wang Xinshuai,Wang Jingfen,Cao Feilin,Du Yingying,Zhang Yongqiang,Chen Lilin,Lu Ping,Sun Sanyuan,Zhang Ruiwen,Zang Aimin,Nie Xiuqing,Lei Yuan
Reference29 articles.
1. NCCN Guidelines� Insights: Breast Cancer, Version 4.2023;W J Gradishar;J Natl Compr Canc Netw,2023
2. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer;S-As-A Im;ESMO open,2023
3. Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guidelines 2022;Z Jiang;Transl breast cancer Res a J Focus Transl Res breast cancer,2022
4. Expert consensus on the clinical diagnosis and targeted therapy of HER2 breast cancer (2023 edition);J Li;Transl Breast Cancer Res,2022
5. Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Thera;A Urruticoechea;J Clin Oncol,2017